Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Effects of proprotein convertase subtilisin-kexin type 9 inhibitors on inflammatory and hemostatic parameters in post myocardial infarction patients
Avtorji:ID Rehberger Likozar, Andreja (Avtor)
ID Ugovšek, Sabina (Avtor)
ID Šebeštjen, Miran (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (1,92 MB)
MD5: 9804FC28ED4DCA5D32373D31BA05FBB9
 
URL URL - Izvorni URL, za dostop obiščite https://www.sciencedirect.com/science/article/pii/S001429992300746X?via%3Dihub
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo UKC LJ - Univerzitetni klinični center Ljubljana
Povzetek:Despite progress in treatment, elevated levels of low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) (Lp(a)), represent a significant part of the residual risk. Both are associated with inflammation and the coagulation fibrinolytic system. The purpose of our research was to evaluate the effect of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) on lipid parameters and indicators of inflammation, coagulation and fibrinolysis. We included 100 post myocardial infarction (MI) patients with insufficiently controlled LDL-C values despite the maximum dose of statin, and highly elevated Lp(a). Patients received alirocumab or evolocumab (150 mg sc or 140 mg sc every two weeks, respectively), or placebo for 6 months. In patients receiving PCSK9i, a significant decrease in total cholesterol (TC), LDL-C, triglycerides (TG) and Lp(a), and an increase in high density lipoprotein cholesterol (p < 0.001 for all) was found. Before treatment, the concentrations of TC, LDL-C and TG correlated with the concentrations of thrombin activatable fibrinolysis inhibitor (r = 0.41, p < 0.001; r = 0.353, p < 0.001; r = 0.311, p = 0.003, respectively), and plasminogen activator inhibitor-1 (r = 0.302, p = 0.007; r = 0.218, p = 0.049; r = 0.278; p = 0.013, respectively). The concentrations of TC and LDL-C correlated with overall fibrinolytic potential (r = −0.220, p = 0.034; r = −0.207, p = 0.047, respectively). The concentration of TG was related to the concentration of interleukin 6 (r = 0.290, p = 0.004) and interleukin 8 (r = 0.332, p = 0.001). No correlations between Lp(a) and inflammatory or hemostatic variables were found. No associations were found after treatment. Our results show that inflammatory cytokines and fibrinolytic parameters are related to LDL-C and not Lp(a) in post-MI patients before and with neither of them following PCSK9i treatment.
Ključne besede:inflammation, hemostasis, PCSK9 inhibitors, LDL cholesterol, lipoprotein (a)
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Leto izida:2024
Št. strani:str. 1-8
Številčenje:Vol. 963, iss. [article no.] 176232
PID:20.500.12556/DiRROS-29837 Novo okno
UDK:616-002
ISSN pri članku:0014-2999
DOI:10.1016/j.ejphar.2023.176232 Novo okno
COBISS.SI-ID:179035139 Novo okno
Datum objave v DiRROS:08.06.2026
Število ogledov:166
Število prenosov:161
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:European Journal of Pharmacology
Skrajšan naslov:Eur. J. Pharmacol.
Založnik:North-Holland
ISSN:0014-2999
COBISS.SI-ID:224279 Novo okno

Gradivo je financirano iz projekta

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P3-0308-2019
Naslov:Ateroskleroza in tromboza

Financer:Drugi - Drug financer ali več financerjev
Program financ.:Univerzitetni klinični center Ljubljana
Številka projekta:20220011
Naslov:Vpliv zaviralcev PCSK9 na celične subpopulacije v periferni krvi bolnikov z ishemično boleznijo srca

Licence

Licenca:CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:vnetje, hemostaza, inhibitorji PCSK9, LDL holesterol, lipoprotein (a)


Nazaj